Ataraxis Real-World Clinical Outcomes Registry Linking AI-Based Pathology Scores to Patient Outcomes

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAtaraxis AI, Inc.

About this trial

The ARC Registry is a large-scale, multi-site, prospective, observational registry. All patients with a solid tumor malignancy who receive Ataraxis testing as part of routine clinical care are eligible for enrollment, which will link Ataraxis test results with short- and long-term patient outcomes to evaluate the real-world performance and clinical utility of Ataraxis tests. The ARC Registry utilizes an adaptable design, where additional Sponsor-led analyses and investigator-initiated ancillary studies can be added after the initial study is opened.

Eligibility criteria

Qualifiers

Aged 18 years or older at the time of consent.

Diagnosis of a solid tumor malignancy, confirmed histologically or cytologically.

Patient is undergoing Ataraxis testing as part of their routine clinical care.

Availability of a pathology specimen.

Disqualifiers

Unable or unwilling to provide informed consent.

Patient for whom an Ataraxis test result was not successfully generated (e.g., due to sample quality, technical failure, or any reason resulting in a non-reportable result).

Trial design

Treatments tested in this trial

  • Ataraxis testing

Treatment groups

1,000 Participants
are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators